Immunic receives US patent notice for a polymorph of vidofludimus calcium in MS therapy, valid until 2039.
Immunic announces a notice of allowance for a composition-of-matter patent of a specific polymorph of vidofludimus calcium in the US. The patent also covers a related method of production. This marks the fourth US patent for vidofludimus calcium in MS therapy. The patent provides protection until 2039, extendable further. Previously granted in Australia, Canada, Indonesia, Japan, and Mexico.
March 20, 2024
3 Articles